The Retatrutide LinkPen delivers 30mg/3mL (300 units) of triple-agonist Retatrutide for powerful weight loss and glucose control. Starting dose: 10 units/day. Designed for daily microdosing with minimal side effects. For research use only.
Retatrutide is a next-generation injectable metabolic peptide, now available in a precision-engineered
30 mg / 3 mL (300-unit) prefilled pen designed for consistent daily microdosing.
Retatrutide is a triple-agonist that activates GLP-1, GIP, and glucagon receptors, delivering superior outcomes in appetite control, fat loss, insulin sensitivity, and overall metabolic efficiency.
Clinical trials have demonstrated greater total fat loss and metabolic improvement compared to both Tirzepatide and Semaglutide.
The LinkPen format allows for smooth titration, precise unit-based dosing, and reduced gastrointestinal side effects compared to large weekly injections.
| Compound | Total Content | Concentration |
|---|---|---|
| Retatrutide | 30 mg per pen | 10 mg/mL (100 mcg per unit) |
This product is intended for research and educational purposes only.
It is not FDA-approved for human use.
All information provided is for informational purposes only.
The purchaser assumes full responsibility for lawful handling and use of this research compound.